WO2002009731A1 - Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches - Google Patents
Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches Download PDFInfo
- Publication number
- WO2002009731A1 WO2002009731A1 PCT/FR2001/002396 FR0102396W WO0209731A1 WO 2002009731 A1 WO2002009731 A1 WO 2002009731A1 FR 0102396 W FR0102396 W FR 0102396W WO 0209731 A1 WO0209731 A1 WO 0209731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament
- carbon monoxide
- chosen
- active product
- inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to a use of carbon monoxide (CO) or of a CO donor for manufacturing all or part of a medicament intended for treating or preventing acute or chronic inflammatory pathologies or conditions, in particular all or part of an inhalable gaseous medicine.
- CO carbon monoxide
- a CO donor for manufacturing all or part of a medicament intended for treating or preventing acute or chronic inflammatory pathologies or conditions, in particular all or part of an inhalable gaseous medicine.
- various anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs (AIS) or other molecules known to have such a action, for example nitric oxide (NO).
- NSAIDs non-steroidal anti-inflammatory drugs
- AIS steroidal anti-inflammatory drugs
- NO nitric oxide
- these products cannot be considered completely satisfactory from a therapeutic point of view because either they cause side effects for the patient, or they have insufficient anti-inflammatory activity to be really effective.
- non-steroidal anti-inflammatory drugs have an effectiveness often related to their gastrointestinal toxicity.
- their administration by oral or even can cause in the patient gastric prouiemes, worse or less severe, up to local hemorrhages of the gastrointestinal tract.
- steroidal anti-inflammatory drugs also generate many side effects and especially a risk of addiction and therefore an obligation to wean the patient.
- gaseous nitric oxide as such or combined with a NO donor molecule, as an anti-inflammatory product, taking into account its probable role in the cascade of inflammation.
- gaseous NO as a pulmonary vasodilator or bronchodilator, as described in document EP-A-560928.
- Nitric oxide has also been proposed, moreover, as a protector of the gastric mucosa during oral administration in combination with a non-steroidal anti-inflammatory product or products.
- CO carbon monoxide
- Oxidase theme basic molecule of the inflammatory system in mammals; endogenous CO probably having a Them oxidase modulator activity.
- the problem which arises is to propose a therapeutic composition which is really effective in combating acute or chronic inflammatory pathologies, in particular which can be administered: . , ⁇ : ⁇ : “ ⁇ IA ⁇ icU-zliei i here ⁇ ⁇ i oie un l ⁇ icc.
- the object of the present invention is then to solve the above problem, that is to say to propose a therapeutic product making it possible to effectively treat inflammatory pathologies, which therapeutic product is also easy to produce industrially.
- hemorrhagic type such as those caused by conventional non-steroidal anti-inflammatory drugs.
- the invention therefore relates to the use of carbon monoxide (CO) or of a carbon monoxide (CO) donor agent in combination with at least one gas chosen from nitrogen monoxide (NO), carbon dioxide. (C0 2 ), helium, oxygen, nitrogen and their mixtures for the manufacture of a medicament or part of a medicament intended to treat or prevent acute or chronic inflammation, bronchoconstriction and / or vasoconstriction in patients with man or animal.
- CO carbon monoxide
- CO carbon monoxide
- CO carbon monoxide
- CO carbon monoxide
- CO carbon monoxide
- the invention also relates to the use of carbon monoxide (CO) or of a carbon monoxide (CO) donor agent in combination with at least one active product with anti-inflammatory action to manufacture a medicament or a part of a medicine intended to treat or prevent acute or chronic inflammation in humans or animals.
- CO carbon monoxide
- CO carbon monoxide
- the invention relates to the use of carbon monoxide (CO) or of a carbon monoxide (CO) donor agent in combination with at least one gas chosen from nitrogen monoxide (NO), carbon dioxide (CO 2 ), helium, oxygen, nitrogen and their mixtures, and at least one active product with anti-inflammatory action to make a drug or part of a drug intended to treat or prevent acute inflammation or chronic in humans or animals.
- CO carbon monoxide
- CO 2 carbon dioxide
- helium oxygen
- nitrogen and their mixtures at least one active product with anti-inflammatory action to make a drug or part of a drug intended to treat or prevent acute inflammation or chronic in humans or animals.
- the invention also relates to the use of carbon monoxide (CO) or of a carbon monoxide (CO) donor agent in combination with at least one active product chosen from ⁇ 2 -stimulants , theophylline and derivatives, bronchodilators anticholinergics and cromones to make a medicine or part of a medicine to treat or prevent bronchoconstriction and / or vasoconstriction in humans or animals.
- CO carbon monoxide
- CO carbon monoxide
- CO carbon monoxide
- the invention also relates to the use of carbon monoxide (CO) or of a carbon monoxide (CO) donor agent in combination with at least one gas chosen from nitrogen monoxide (NO ), carbon dioxide (CO 2 ), helium, oxygen, nitrogen and their mixtures, and at least one active product chosen from ⁇ 2 - stimulants, theophylline and derivatives, anticholinergic bronchodilators and cromones for manufacturing a medicament or part of a medicament intended to treat or prevent bronchoconstriction and / or vasoconstriction in humans or animals.
- CO carbon monoxide
- CO carbon monoxide
- CO carbon monoxide
- carbon monoxide (CO) donor agent means one or more molecules, or one or more products or substances capable of fixing and / or transporting one or more molecules of CO and subsequently to release and / or release the said CO molecule (s), in particular after its administration to humans or animals, for example at or in the target organ to be treated.
- endogenous CO that is to say CO synthesized directly by the body of man or animal
- the use of the invention may include one or more of the following characteristics:
- the medicament or the part of the said medicament also contains at least one additional gas chosen from xenon, hydrogen, protoxide nitrogen (N 2 O), argon, neon, krypton, carbonaceous or fluorocarbon hydrocarbons, and mixtures of several of these gases.
- the carbonaceous or fluoro-carbonaceous hydrocarbons which can be used are conventionally gases or gas mixtures based on heptafluoropropane, tetrafluoroethane or other similar gases which may also contain hydrogen.
- the active product with anti-inflammatory action is chosen from steroidal anti-inflammatory drugs (AIS), in particular corticosteroids and mineralosterol ' , such as prednisone, dexa and methylprednisolone.
- AIS steroidal anti-inflammatory drugs
- mineralosterol ' such as prednisone, dexa and methylprednisolone.
- NSAIDs non-steroidal anti-inflammatory drugs
- the active product is chosen from indoliques and derivatives, for example Tindometacin; arylcarboxylics, for example ketoprofen or arylpropionic acid; oxicam derivatives, such as pyroxycam or fenamates; salicylates, for example acetylsalicylic acid, theophylline and derivatives, anticholinergic bronchodilators and cromones, such as cromoglycate, and mixtures thereof.
- indoliques and derivatives for example Tindometacin
- arylcarboxylics for example ketoprofen or arylpropionic acid
- oxicam derivatives such as pyroxycam or fenamates
- salicylates for example acetylsalicylic acid, theophylline and derivatives, anticholinergic bronchodilators and cromones, such as cromoglycate, and mixtures thereof.
- the active product is chosen from anticholinergic bronchodilators, such as ipratropium bromide, theophylline and derivatives, anticholinergic bronchodilators and cromones, such as cromoglycate,
- the medicament or the part of medicament is in inhalable form, preferably in gaseous or aerosol form.
- the ⁇ 2 -stimulants are for example chosen from the following compounds: terbutaline, salbutamol and salmeterol.
- the medicament is intended to treat or prevent an inflammatory pathology, a vasoconstriction or a bronchoconstriction of the upper airways or of the bronchial tree in humans or animals, preferably a pathology chosen from asthma, pneumopathies, cystic fibrosis and bronchopneumopathies.
- the drug is intended to treat or prevent a systemic inflammatory pathology such as polyarteritis nodosa (PAN), rheumatoid arthritis (RA), and rheumatoid arthritis.
- PAN polyarteritis nodosa
- RA rheumatoid arthritis
- rheumatoid arthritis rheumatoid arthritis
- CO carbon monoxide
- the carbon monoxide donor agent is used in the composition of a drug which can be administered by inhaled, enteral, parenteral, transcutaneous or transdermal route.
- the drug contains a therapeutically effective amount of carbon monoxide (CO), preferably the amount of CO is between 1 ppb and 1000 ppm, preferably less than 600 ppm.
- CO carbon monoxide
- the invention also relates to a gas mixture chosen from CO / O2, CO / N 2 , CO / NO / N 2 , CO / CO 2 , CO / He, CO / N 2 O, Ar / CO,
- Kr / CO, Ne / CO as a medicament or part of a medicament to be inhaled, said mixture possibly containing, in addition, from 10 to 30% by volume of oxygen, for example a CO / N 2 O / O 2 or CO / He / O 2 .
- the gas mixture contains (by volume) from 100 ppb to
- the invention also relates to the drug or pharmaceutical preparation in the form of a gas mixture or an aerosol comprising a therapeutically effective proportion of carbon monoxide (CO) or of a donor agent of monoxide of carbon (CO) and:
- Toxygene nitrogen, xenon, hydrogen, carbon dioxide, argon, nitrogen monoxide (NO), nitrous oxide (N 2 O), carbonaceous, fluoro-carbon and mixtures of many of these gases
- NSAIDs non-steroidal anti-inflammatory drugs
- NSAIDs steroidal anti-inflammatory drugs
- the present invention is based on the demonstration by the inventors that carbon monoxide (CO), usually presented as a toxic gas, can be used for therapeutic purposes and, more specifically, that CO can have a therapeutic activity due to its anti-proliferative, anti-aggregating platelet, anti-inflammatory, bronchodilator and vasodilator properties.
- CO carbon monoxide
- CO carbon monoxide
- the CO molecule acts essentially in two ways on the inflammatory process, namely: - CO selectively inhibits the expression of proinflammatory agents, such as TNF-alpha, interleukin-1beta and macrophage inflammatory-1 beta. These agents usually play an important role in the inflammatory process.
- proinflammatory agents such as TNF-alpha, interleukin-1beta and macrophage inflammatory-1 beta.
- - CO activates and modulates the release of anti-inflammatory agents, such as Tinterleukin 10.
- CO activity is more likely linked to another pathway involving an activated mitogenic protein kinase (MAP).
- MAP mitogenic protein kinase
- CO can be administered by inhalation, i.e. CO is administered to the patient via their respiratory tract using a CO delivery device, such as a ventilator connect a source of CO so as to administer the CO to the patient via a respiratory mask, respiratory glasses or a cannula.
- a CO delivery device such as a ventilator connect a source of CO so as to administer the CO to the patient via a respiratory mask, respiratory glasses or a cannula.
- Administration of CO gas can be done either continuously or in a pulsed manner, that is to say during all or part of each inspiratory phase of the patient.
- the detection of the beginning and / or the end of each inspiratory and / or expiratory phase is conventionally done by means of a device adapted for this purpose.
- the respiratory gas administered to the patient contains, in addition to the CO or the CO donor, toxygene in a non-hypoxic amount, i.e. say a proportion sufficient to ensure correct ventilation of the patient, such as air or a gas mixture containing in the order of 19 to 23% oxygen, the remainder being one or more inert gases, such as nitrogen.
- a non-hypoxic amount i.e. say a proportion sufficient to ensure correct ventilation of the patient, such as air or a gas mixture containing in the order of 19 to 23% oxygen, the remainder being one or more inert gases, such as nitrogen.
- carbon monoxide (CO) or the carbon monoxide (CO) donor agent is used according to the invention in combination with one or more other gases and / or with at least one product.
- active with anti-inflammatory action can lead to a significant improvement in the effect of the active product with anti-inflammatory action in the presence of CO compared to a use of the same product but without CO.
- CO due to its raised properties, CO sometimes leads to an improving or synergistic effect of the action of the active product by making it possible to facilitate the assimilation of said active product by the patient.
- certain gases such as NO.
- the drug mixtures according to the invention can be manufactured not only directly on their site of use and just before their administration to the patient but also in a site for packaging pharmaceutical products, such as a pharmaceutical manufacturing laboratory, before to be sent in packaged form to their site of use.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01956632A EP1307208A1 (fr) | 2000-07-27 | 2001-07-23 | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
AU2001278558A AU2001278558A1 (en) | 2000-07-27 | 2001-07-23 | Use of co for treating inflammation of upper airways or bronchi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0009881A FR2812197B1 (fr) | 2000-07-27 | 2000-07-27 | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
FR00/09881 | 2000-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002009731A1 true WO2002009731A1 (fr) | 2002-02-07 |
Family
ID=8852996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/002396 WO2002009731A1 (fr) | 2000-07-27 | 2001-07-23 | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1307208A1 (fr) |
AU (1) | AU2001278558A1 (fr) |
FR (1) | FR2812197B1 (fr) |
WO (1) | WO2002009731A1 (fr) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105871A1 (fr) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Protection cerebrale a l'aide d'un gaz contenant du xenon |
WO2003105872A1 (fr) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Spasmolytique a base de xenon |
FR2849779A1 (fr) * | 2003-01-15 | 2004-07-16 | Air Liquide Sante Sa | Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques |
EP1515753A1 (fr) * | 2002-06-21 | 2005-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Utilisation pharmaceutique du monoxyde d'azote, de l'heme oxygenase-1 et des produits de la degradation de l'heme |
WO2005039600A2 (fr) * | 2003-10-21 | 2005-05-06 | Aga Ab | Emploi du xenon pour contrer la mort programmee des cellules |
EP1552840A1 (fr) * | 2004-01-07 | 2005-07-13 | Aga Ab | Mélange de xénon et de monoxyde de carbone pour la protection de cellules |
EP1558084A2 (fr) * | 2002-11-07 | 2005-08-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Traitement pour choc hemorragique |
WO2007071052A1 (fr) * | 2005-12-21 | 2007-06-28 | Uti Limited Partnership | Traitement de maladies respiratoires |
US7238469B2 (en) | 2001-06-21 | 2007-07-03 | Beth Israel Deaconess Medical Center, Inc. | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US7364757B2 (en) | 2002-02-13 | 2008-04-29 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating vascular disease |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7687079B2 (en) | 2002-04-15 | 2010-03-30 | University of Pittsburgh of the Commonwealth System of Higher Education Yale University | Methods of treating ileus |
US7981448B2 (en) | 2002-04-15 | 2011-07-19 | University Of Pittsburgh | Methods of treating necrotizing enterocolitis |
WO2011098698A1 (fr) * | 2010-02-15 | 2011-08-18 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Médicament gazeux inhalable à base d'argon contre les déficiences ou défaillances d'organes périphériques |
FR2960779A1 (fr) * | 2010-06-08 | 2011-12-09 | Air Liquide | Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037644A1 (fr) * | 1996-04-05 | 1997-10-16 | The General Hospital Corporation | Traitement d'un type d'hemoglobinose |
WO1998008523A1 (fr) * | 1996-08-27 | 1998-03-05 | Messer Griesheim Gmbh | Medicament contenant de l'hydrogene |
-
2000
- 2000-07-27 FR FR0009881A patent/FR2812197B1/fr not_active Expired - Fee Related
-
2001
- 2001-07-23 WO PCT/FR2001/002396 patent/WO2002009731A1/fr not_active Application Discontinuation
- 2001-07-23 AU AU2001278558A patent/AU2001278558A1/en not_active Abandoned
- 2001-07-23 EP EP01956632A patent/EP1307208A1/fr not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037644A1 (fr) * | 1996-04-05 | 1997-10-16 | The General Hospital Corporation | Traitement d'un type d'hemoglobinose |
WO1998008523A1 (fr) * | 1996-08-27 | 1998-03-05 | Messer Griesheim Gmbh | Medicament contenant de l'hydrogene |
Non-Patent Citations (1)
Title |
---|
See also references of EP1307208A1 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7238469B2 (en) | 2001-06-21 | 2007-07-03 | Beth Israel Deaconess Medical Center, Inc. | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US7691416B2 (en) | 2002-02-13 | 2010-04-06 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
US7364757B2 (en) | 2002-02-13 | 2008-04-29 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating vascular disease |
US7687079B2 (en) | 2002-04-15 | 2010-03-30 | University of Pittsburgh of the Commonwealth System of Higher Education Yale University | Methods of treating ileus |
US7981448B2 (en) | 2002-04-15 | 2011-07-19 | University Of Pittsburgh | Methods of treating necrotizing enterocolitis |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
JP2005533062A (ja) * | 2002-06-12 | 2005-11-04 | メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | キセノン含有ガスによる脳保護 |
US7235264B2 (en) | 2002-06-12 | 2007-06-26 | Air Liquide Deutschland Gmbh | Cerebral protection with a gas comprising xenon |
WO2003105871A1 (fr) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Protection cerebrale a l'aide d'un gaz contenant du xenon |
WO2003105872A1 (fr) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Spasmolytique a base de xenon |
EP1515753A1 (fr) * | 2002-06-21 | 2005-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Utilisation pharmaceutique du monoxyde d'azote, de l'heme oxygenase-1 et des produits de la degradation de l'heme |
EP1515753A4 (fr) * | 2002-06-21 | 2009-07-15 | Univ Pittsburgh | Utilisation pharmaceutique du monoxyde d'azote, de l'heme oxygenase-1 et des produits de la degradation de l'heme |
EP1558084A4 (fr) * | 2002-11-07 | 2008-04-30 | Univ Pittsburgh | Traitement pour choc hemorragique |
EP1558084A2 (fr) * | 2002-11-07 | 2005-08-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Traitement pour choc hemorragique |
EP1438963A1 (fr) * | 2003-01-15 | 2004-07-21 | Air Liquide Santé (International) | Utilisation de N2O dans le traitement des détériorations cellulaires cérébrales post-ischémiques |
FR2849779A1 (fr) * | 2003-01-15 | 2004-07-16 | Air Liquide Sante Sa | Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques |
US7405241B2 (en) | 2003-01-15 | 2008-07-29 | Air Liquide Sante (International) | Use of N2O in the treatment of post-ischemic brain cell deterioration |
WO2005039600A2 (fr) * | 2003-10-21 | 2005-05-06 | Aga Ab | Emploi du xenon pour contrer la mort programmee des cellules |
WO2005039600A3 (fr) * | 2003-10-21 | 2005-10-13 | Aga Ab | Emploi du xenon pour contrer la mort programmee des cellules |
WO2005067945A2 (fr) * | 2004-01-07 | 2005-07-28 | Aga Ab | Utilisation d'un melange de xenon/monoxyde de carbone pour la protection de cellules |
EP1552840A1 (fr) * | 2004-01-07 | 2005-07-13 | Aga Ab | Mélange de xénon et de monoxyde de carbone pour la protection de cellules |
WO2005067945A3 (fr) * | 2004-01-07 | 2006-03-02 | Aga Ab | Utilisation d'un melange de xenon/monoxyde de carbone pour la protection de cellules |
WO2007071052A1 (fr) * | 2005-12-21 | 2007-06-28 | Uti Limited Partnership | Traitement de maladies respiratoires |
US8454938B2 (en) | 2005-12-21 | 2013-06-04 | Solaeromed Inc. | Treatment of respiratory diseases |
WO2011098698A1 (fr) * | 2010-02-15 | 2011-08-18 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Médicament gazeux inhalable à base d'argon contre les déficiences ou défaillances d'organes périphériques |
FR2956323A1 (fr) * | 2010-02-15 | 2011-08-19 | Air Liquide | Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques |
CN102740864A (zh) * | 2010-02-15 | 2012-10-17 | 乔治洛德方法研究和开发液化空气有限公司 | 对抗外周器官缺陷或衰竭的基于氩的可吸入的气体药物 |
JP2013519660A (ja) * | 2010-02-15 | 2013-05-30 | レール・リキード−ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 周辺器官の疾病又は障害に対するアルゴン系の吸入可能なガス状治療薬 |
CN102740864B (zh) * | 2010-02-15 | 2014-05-21 | 乔治洛德方法研究和开发液化空气有限公司 | 对抗外周器官缺陷或衰竭的基于氩的可吸入的气体药物 |
WO2011154630A1 (fr) * | 2010-06-08 | 2011-12-15 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Médicament gazeux inhalable à base de krypton contre les déficiences ou défaillance d'organes périphériques |
FR2960779A1 (fr) * | 2010-06-08 | 2011-12-09 | Air Liquide | Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques |
Also Published As
Publication number | Publication date |
---|---|
FR2812197A1 (fr) | 2002-02-01 |
EP1307208A1 (fr) | 2003-05-07 |
FR2812197B1 (fr) | 2003-01-03 |
AU2001278558A1 (en) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1307208A1 (fr) | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches | |
EP1177793B1 (fr) | Aérosol médicamenteux inhalable dans le traitement ou la prévention de la douleur | |
ES2779273T3 (es) | Formulación superfina de formoterol | |
JP4652664B2 (ja) | Gsnoの充足を起こすガス状薬剤による肺疾患の処置 | |
ES2309503T3 (es) | Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos. | |
ES2402618T3 (es) | Usos y medios para obtener relajación bronquial | |
JP2002512978A (ja) | ニコチン含有溶液 | |
Rasmussen et al. | Comparison of xenon with propofol for supplementary general anaesthesia for knee replacement: a randomized study | |
FR2816212A1 (fr) | Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire | |
JP5370851B2 (ja) | パラセタモールの径粘膜投与のためのガレヌス製剤 | |
EP2536415B1 (fr) | Médicament gazeux inhalable à base d'argon contre les déficiences ou défaillances d'organes périphériques | |
EA022312B1 (ru) | Монотерпены для лечения заболеваний дыхательных путей, в частности бронхолегочных заболеваний | |
LU87615A1 (fr) | Solution pharmaceutique | |
EP1064945B1 (fr) | Utilisations thérapeutiques d'un mélange helium/oxygene, en particulier dans le traitement de l'asthme | |
WO2011154630A1 (fr) | Médicament gazeux inhalable à base de krypton contre les déficiences ou défaillance d'organes périphériques | |
JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
WO2014057180A1 (fr) | Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique | |
ES2935684T3 (es) | Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades | |
FR3123803A3 (fr) | Mélange gazeux utilisable en cas d’accident vasculaire cérébral ischémique | |
FR3123802A3 (fr) | Mélange gazeux à base d’argon et d’hélium utilisable en cas d’accident vasculaire cérébral ischémique | |
EP3868361A1 (fr) | Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients sous opioïdes | |
JPWO2019197406A5 (fr) | ||
JPH02131421A (ja) | 肝障害抑制剤 | |
Berg et al. | Novel approaches to drug delivery in critical care | |
JPH11335272A (ja) | 呼吸機能障害の予防及び/又は治療用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001956632 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001956632 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWR | Wipo information: refused in national office |
Ref document number: 2001956632 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001956632 Country of ref document: EP |